Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.
New York City
Friday, October 4 at 7:45 a.m. Eastern time (ET).
August 9, 2019
Geneva, Switzerland and Boston, MA – August 9, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical…Read more
August 7, 2019
Geneva, Switzerland and Boston, MA – August 7, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage…Read more
Multiple Major Milestones Expected This Year Q4:19 Phase 3 data for IMPLANT 4 trial of nolasiban Nolasiban MAA…Read more
May 8, 2019
May 9, 2018
March 2, 2020
November 11, 2019
October 17, 2019